Search Within

Alexander Edward Drilon

Formats
  1. Meeting Abstract (373)
  2. Journal Article (219)
  3. Review (23)
  4. Editorial (6)
  5. Correspondence (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Book Whole (1)
  9. Guidelines (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (631)
  2. Solid Tumor Oncology Division (631)
  3. Thoracic Oncology (631)
  4. Department of Pathology and Laboratory Medicine (205)
  5. GSK Faculty (187)
  6. Human Oncology and Pathogenesis Program (156)

More Groups

People
  1. Marc Ladanyi (121)
  2. Mark Kris (89)
  3. Maria Arcila (82)
  4. David Hyman (78)
  5. Bob Li (65)
  6. Charles Rudin (64)

More People

Years
  1. 2025 (16)
  2. 2024 (61)
  3. 2023 (67)
  4. 2022 (85)
  5. 2021 (76)
  6. 2020 (81)

More Years

Publications
  1. Journal of Clinical Oncology (138)
  2. Annals of Oncology (94)
  3. Journal of Thoracic Oncology (84)
  4. Clinical Cancer Research (31)
  5. JCO Precision Oncology (24)
  6. Cancer Research (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (164)
  2. Elsevier Inc. (118)
  3. Oxford University Press (113)
  4. American Association for Cancer Research (77)
  5. Nature Publishing Group (27)
  6. S. Karger AG (23)

More Publishers

Results (631)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Lurbinectedin (PM01183) in combination with paclitaxel (P) in patients (pts) with advanced solid tumors
    Meeting Abstract

    Garralda, E.; Stathis, A.; Drilon, A.; Boni, V.; Hyman, D.; Calvo, E.; Griguolo, G.; Makker, V.; Doger, B.; Canziani, L.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors
    Journal Article

    Davare, M. A.; Vellore, N. A.; Wagner, J. P.; Eide, C. A.; Goodman, J. R.; Drilon, A.; Deininger, M. W.; O'Hare, T.; Druker, B. J.
    Proceedings of the National Academy of Sciences of the United States of America (2015)

    Fulltext@MSK | Save
  • Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches
    Journal Article

    Drilon, A.; Wang, L.; Arcila, M. E.; Balasubramanian, S.; Greenbowe, J. R.; Ross, J. S.; Stephens, P.; Lipson, D.; Miller, V. A.; Kris, M. G.; more...
    Clinical Cancer Research (2015)

    Fulltext@MSK | Save
  • STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations
    Meeting Abstract

    Patel, M. R.; Bauer, T. M.; Liu, S. V.; Drilon, A. E.; Wheler, J. J.; Shaw, A. T.; Farago, A. F.; Ou, S. H. I.; Luo, D.; Yeh, L.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping
    Meeting Abstract

    Paik, P. K.; Drilon, A. E.; Yu, H. A.; Krug, L. M.; Rekhtman, N.; Borsu, L.; Ginsberg, M. S.; Berger, M. F.; Ladanyi, M.; Rudin, C. M.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase II trial of bortezomib in KRAS G12D mutant lung cancers
    Meeting Abstract

    Litvak, A. M.; Drilon, A. E.; Rekhtman, N.; Pietanza, M. C.; Chaft, J. E.; Woo, K.; Paik, P. K.; Kris, M. G.; Riely, G. J.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase 1, open-label, dose-escalation study of SNX-5422 plus carboplatin and paclitaxel in subjects with advanced lung cancers
    Meeting Abstract

    Gutierrez, M.; Giaccone, G.; Harper, H. D.; Liu, S. V.; Fang, B.; Ruiz, J.; Hinson, J. M.; Orlemans, E. O.; Drilon, A. E.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial of the HSP-90 inhibitor PU-H71
    Meeting Abstract

    Gerecitano, J. F.; Modi, S.; Rampal, R.; Drilon, A. E.; Fury, M. G.; Gounder, M. M.; Harding, J. J.; Hyman, D. M.; Varghese, A. M.; Voss, M. H.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Physician toxicity attribution in phase I trials: Evaluating the effect of dose on the frequency of 11,909 toxicities
    Meeting Abstract

    Eaton, A.; Iasonos, A.; Gounder, M. M.; Pamer, E.; Drilon, A. E.; Vulih, D.; Smith, G. L.; Ivy, P.; Spriggs, D. R.; Hyman, D. M.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers
    Meeting Abstract

    Drilon, A. E.; Sima, C. S.; Somwar, R.; Smith, R.; Ginsberg, M. S.; Riely, G. J.; Rudin, C. M.; Ladanyi, M.; Kris, M. G.; Rizvi, N. A.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save